Arterys IPO
Arterys developed cloud-based medical imaging software powered by AI for analyzing cardiac, liver, and lung conditions. The company was known for its FDA-cleared AI platform that helped radiologists quantify medical imaging data more efficiently. The acquisition reflected the strategic value of AI-powered medical imaging technology.
Key Facts
| Industry | Medical AI |
| Founded | 2011 |
| Headquarters | San Francisco, CA |
| Employees | Acquired (previously ~100) |
| Website | arterys.com |
| Funding | Acquired by Tempus in 2021. Previously raised ~$50M in venture funding |
About Arterys
Arterys pioneered cloud-based medical imaging AI, developing FDA-cleared algorithms that assist radiologists in analyzing cardiac MRI, oncology, and lung imaging studies. The company's platform combines advanced deep learning models with cloud computing infrastructure to provide real-time image analysis and quantitative measurements that improve diagnostic accuracy and workflow efficiency in hospitals and imaging centers.
Arterys was notable for receiving some of the first FDA clearances for cloud-based AI medical devices, establishing important regulatory precedents for the medical AI industry. The company's technology addressed critical pain points in radiology, where image analysis can be time-intensive and subject to variability between readers. Arterys was acquired by Tempus in 2021, integrating its imaging AI capabilities into Tempus's broader precision medicine platform focused on oncology and other therapeutic areas.
IPO Status
Arterys was acquired by Tempus in 2021, preventing any potential IPO plans the company may have had. Tempus, an AI-enabled precision medicine company, integrated Arterys' medical imaging capabilities into its broader healthcare technology platform. Prior to the acquisition, Arterys had raised venture funding and built partnerships with major imaging equipment manufacturers. The acquisition by Tempus represented an exit for Arterys investors and employees, eliminating the possibility of an independent public offering.
Competitors
Frequently Asked Questions
Does Arterys have a stock?
No, Arterys did not have an IPO. The company was acquired by Tempus in 2021 before going public.
When is the Arterys IPO date?
There will be no Arterys IPO as the company was acquired by Tempus in 2021. Arterys no longer operates as an independent company.
How can I buy Arterys stock?
You cannot buy Arterys stock as the company was acquired by Tempus and no longer trades independently. Arterys' technology is now part of Tempus' platform.
Don't Miss the Next Big IPO
Get notified when the next major company files for an IPO. Daily alerts delivered to your inbox.
Get IPO Alerts